The Approval Process in Action

Life Sciences Tools & DiagnosticsMedical DevicesRegenerative MedicineBiotechnology / Pharmaceuticals

Source: The Life Sciences Report and Visual Capitalist (5/1/13)

What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.

New Data, Analyst Calls, and Pipeline Milestones Put Spotlight on Next Wave of Weight-Loss Drug Developers
Source: Streetwise Reports (02/18/2026)

Eli Lilly (LLY:NYSE), Amgen (AMGN:NASDAQ), and Structure Therapeutics (GPCR:NASDAQ) were cited in recent reports and corporate updates tied to the expanding GLP-1 and obesity treatment market. Analyst commentary, clinical developments, and pipeline milestones highlighted ongoing activity across the sector.

Biotech Company Advances Breakthrough Hyperinsulinism Treatment
Source: Streetwise Reports (02/13/2026)

Rezolute Inc. (RZLT:NASDAQ), a late-stage company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), reports its financial results and provides a business update for the three months ending December 31, 2025. Read why one analyst considers the stock a Buy.

CleanTech Company Advances FDA-Cleared Solution Toward Big Gains
Source: Streetwise Reports (02/10/2026)

Clean technology and life sciences company BioLargo Inc. (BLGO:OTCQX) announces that its subsidiary, Clyra Medical Technologies, Inc., has received its first commercial stocking order for ViaCLYR, its FDA-cleared wound irrigation solution. Read why one analyst believes the company has made significant progress in several initiatives.

Arch Biopartners Inc (ARCH:TSXV; ACHFF:OTCQB) is a therapeutic biotech company focused on developing novel, on-target drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The companys board and scientific advisory team of seasoned pros includes Dr. Patrick Vink (M.D., M.B.A.), Chairman of the Board, and Dr. Dan Muruve (M.D.), Chief Scientific Officer and internationally recognized nephrologist. The technical action on the charts suggests a significant surge in the stock price could be imminent.

Experts Spotlight a Persistent Barrier in Advanced Cancer Therapies
Source: Streetwise Reports (02/09/2026)

Rakovina Therapeutics Inc. (RKV:TSX.V) outlined its AI-driven approach to brain-penetrant ATR and mTOR inhibitors during the 9th Annual DNA Damage Response Inhibitors Summit in Boston. The company also reported inbound interest in its kt-3000 series as potential payloads for antibody-drug conjugates.